Inovio Pharmaceuticals, Inc. INO
Inovio Pharmaceuticals, Inc. (Nasdaq: INO) is an infectious disease drug developer. Its lead program, INO-3107, is in Phase 3 for recurrent respiratory papillomatosis (RRP) in adults. Its next catalyst on record is INO-3107: Potential commercial launch following approval (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: INO-3107 — Potential commercial launch following approval (Q1 2027). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| INO-3107 (with CELLECTRA device) | recurrent respiratory papillomatosis | device-combination | Phase 3 |
| INO-3112 + LOQTORZI (toripalimab) | HPV-16/-18 positive locoregionally advanced oropharyngeal squamous cell carcinoma | device-combination | Phase 2 |
| INO-5412 + Akeso PD-1/CTLA-4 inhibitor | glioblastoma | device-combination | Phase 2 |
| HPV-related anal dysplasia candidate | HPV-related anal dysplasia | device-combination | Phase 1 |
| Ebola vaccine booster candidate | Ebola | vaccine | Phase 1 |
| DPROT / DMAb programs | Fabry disease, hypophosphatasia (rare disease), others | biologic-other | Pre-clinical |
Recent results and decisions
- Nov 2, 2026met Seven out of 26 patients (27%) demonstrated complete response with no surgical excisions in 12 months after treatment.
Seven out of the 26 patients (27% [95% CI: 12; 48%]) demonstrated a complete response, defined as requiring no surgical excision of papillomas, after 12 months of follow up.
Filing - Nov 2, 2026submitted FDA requires INOVIO to submit a draft protocol for a confirmatory study by the end of 2026.
The FDA requires INOVIO to submit a draft protocol for the study by the end of 2026 with the expectation of aligning on a final protocol by mid-2027.
Filing - Nov 2, 2026positive RRP-001 study showed 27% of patients requiring no surgical excision of papillomas after 12 months of follow-up.
Seven out of the 26 patients (27% [95% CI: 12; 48%]) demonstrated a complete response, defined as requiring no surgical excision of papillomas, after 12 months of follow up.
Filing
5 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 infectious disease companies
- GSK plc GSK
- Vaxcyte, Inc. PCVX
- Sinovac Biotech Ltd SVA
- Valneva SE VALN
- Kamada Ltd KMDA
- CorMedix Inc. CRMD
- Atea Pharmaceuticals, Inc. AVIR
- SIGA Technologies, Inc. SIGA
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.